Denis B. Buxton, Ph.D.
Denis B. Buxton, Ph.D., joined the National Heart, Lung, and Blood Institute (NHLBI) as a senior fellow in 1996. Dr. Buxton was appointed Assistant Director of the Heart Research Program in NHLBI's Division of Heart and Vascular Diseases in 2001 and a year later took on an additional role as a Health Science Administrator in the Institute's Bioengineering and Genomics Applications Group. In 2005, he was appointed Acting Director of the Heart Research Program. In 2006, he became Chief, Advanced Technologies & Surgery Branch in the Division of Cardiovascular Diseases. Currently Dr. Buxton is Associate Director of the Basic and Early Translational Research Program.
Dr. Buxton's areas of research interest are molecular imaging, nanotechnology, myocardial ischemia and reperfusion, and stem cell transplantation. Dr. Buxton earned a B.Sc. in biochemistry in 1977 at University College, London, UK. In 1980 he earned a Ph.D. in biochemistry from the same institution. Prior to joining NHLBI, Dr. Buxton served as a research instructor from 1983 to 1985 in the Department of Biochemistry, at the University of Texas Health Science Center, San Antonio. He then went on to the University of California, Los Angeles School of Medicine where he served as Associate Professor in the Department of Radiological Sciences from 1991-1992, followed by an Associate Professorship in the Department of Molecular and Medical Pharmacology from 1993 to 1996. The author or coauthor of 68 papers, book chapters, letters, and review articles, Dr. Buxton earned the NHLBI Director's Award 2005 and gave the 19th Annual William Burch Memorial Lecture at the 2005 meeting of the Association of University Cardiologists. He is a reviewer for several prestigious medical journals, including Circulation, Lancet, the American Journal of Physiology, the Journal of Biological Chemistry, and Cardiovascular Research, among others.
Areas of Expertise: Molecular imaging, nanotechnology, myocardial ischemia and reperfusion, and stem cell transplantation.
Dr. Buxton In the News
An NIH-supported study in mice suggests that new heart cells arise from pre-existing heart cells and that the renewal process slows with age. The findings may lead to improved regenerative therapy for people with heart damage.
In an NHLBI-funded study. that could help advance the field of regenerative medicine for years to come, the Interdisciplinary Stem Cell Institute at the Miller School has found that mesenchymal stem cells, whether from patients or donors, can treat people whose hearts were previously damaged and scarred after a heart attack.